Oh Hyewon, Chung Yong Eun, You Je Sung, Joo Chan Gyu, Kim Pan Ki, Lim Joon Seok, Kim Myeong-Jin
Department of Radiology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea.
BK21PLUS project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Magn Reson Med. 2020 Oct;84(4):2124-2132. doi: 10.1002/mrm.28249. Epub 2020 Mar 11.
To compare gadolinium retention in the abdominal organs after administration of gadoxetic acid disodium, a liver-specific contrast agent, compared to gadodiamide and gadobutrol.
Three types of gadolinium-based contrast agents (GBCAs) were administered to rats. A single (gadodiamide and gadobutrol, 0.1 mmol/kg; gadoxetic acid disodium, 0.025 mmol/kg) or double label-recommended dose was intravenously administered once (Group 1), a single dose was administered 4 times (Group 2) and a single dose with or without a chelating agent (intraperitoneal injection immediately after each GBCA administration) was administered (Group 3). Rats were sacrificed after 1, 4, and 12 weeks and gadolinium concentrations in the liver, spleen, kidney, muscle, and bone were measured by inductively coupled plasma mass spectrometry. P values less than 0.05 were considered statistically significant.
More gadolinium was retained with a double dose compared to a single dose, but there was no observed significant difference in gadolinium retention after a double dose compared to a single dose (P > .05). Gadodiamide was retained the most in all tissues followed by gadobutrol and gadoxetic acid disodium. Residual gadolinium was significantly less at 4 weeks compared to 1 week (P < .05), but no further decrease was observed after 4 weeks (P > .05). The presence of the chelating agent did not significantly decrease the concentration of residual gadolinium (P > .05).
Gadolinium was retained the least in abdominal organs after gadoxetic acid disodium was administered and most of the residual gadolinium was excreted 4 weeks after GBCA administration when a label-recommended dose was administered. A commercially available chelation therapy agent could not reduce gadolinium retention.
比较肝脏特异性造影剂钆塞酸二钠与钆喷酸葡胺和钆布醇给药后钆在腹部器官中的潴留情况。
给大鼠施用三种类型的钆基造影剂（GBCAs）。单次（钆喷酸葡胺和钆布醇，0.1 mmol/kg；钆塞酸二钠，0.025 mmol/kg）或双标签推荐剂量静脉注射一次（第1组），单次剂量给药四次（第2组），并给予单次剂量加或不加螯合剂（每次GBCA给药后立即腹腔注射）（第3组）。在1、4和12周后处死大鼠，通过电感耦合等离子体质谱法测量肝脏、脾脏、肾脏、肌肉和骨骼中的钆浓度。P值小于0.05被认为具有统计学意义。
与单次剂量相比，双剂量时钆的潴留更多，但双剂量与单次剂量相比，钆潴留未见显著差异（P>.05）。钆喷酸葡胺在所有组织中的潴留最多，其次是钆布醇和钆塞酸二钠。与1周相比，4周时残留钆显著减少（P<.05），但4周后未观察到进一步下降（P>.05）。螯合剂的存在并未显著降低残留钆的浓度（P>.05）。
施用钆塞酸二钠后，钆在腹部器官中的潴留最少，当给予标签推荐剂量时，大部分残留钆在GBCA给药后4周排出。市售的螯合治疗剂不能降低钆的潴留。
